In vitro evaluation of cefixime (FK027, FR17027, CL284635): Spectrum against recent clinical isolates, comparative antimicrobial activity, β-lactamase stability, and preliminary susceptibility testing criteria

1986 ◽  
Vol 5 (2) ◽  
pp. 151-162 ◽  
Author(s):  
Peter C. Fuchs ◽  
Ronald N. Jones ◽  
Arthur L. Barry ◽  
Clyde Thornsberry ◽  
Leona W. Ayers ◽  
...  
2011 ◽  
Vol 5 (23) ◽  
pp. 3884-3889 ◽  
Author(s):  
Ramasamy Pasiyappazham ◽  
Subhapradha Namasivayam ◽  
Srinivasan Alagiri ◽  
Shanmugam Vairamani ◽  
Krishnamoorthy Jayalakshmi ◽  
...  

2014 ◽  
Vol 15 (6) ◽  
pp. 583-588 ◽  
Author(s):  
Boris Pejin ◽  
Carmine Iodice ◽  
Giuseppina Tommonaro ◽  
Bojana Stanimirovic ◽  
Ana Ciric ◽  
...  

1998 ◽  
Vol 42 (2) ◽  
pp. 471-472 ◽  
Author(s):  
M. Hong Nguyen ◽  
Christine Y. Yu

ABSTRACT In vitro susceptibility testing for 50 clinical isolates of fluconazole-susceptible or -resistant Cryptococcus neoformans was performed with itraconazole and voriconazole. Voriconazole was more potent than itraconazole for fluconazole-susceptible isolates and as potent as itraconazole for fluconazole-susceptible dose-dependent isolates and for fluconazole-resistant isolates. For fluconazole-resistant isolates, the voriconazole and itraconazole MICs ranged from 1 to 2 μg/ml.


Sign in / Sign up

Export Citation Format

Share Document